Condition: Acute Treatment of Migraine · Sponsor: Pfizer
Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack. International Headache Society (IHS) global practice recommendations for the Acute Treatment of Migraine suggest a second dose of the same medication within the recommended dose limit in people with headache relapse after successful initial treatment of a migraine attack. The primary purpose of this study is to evaluate the safety and tolerability of redosing of rimegepant when taken for the acute treatment of a migraine attack, as it is possible that some patients may benefit from a second dose of rimegepant in this setting.
This description comes directly from the study's public registry record.
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
Always discuss trial participation with your own doctor first.
| Hope Clinical Research | Canoga Park, California, United States | Recruiting |
| Neurology Offices of South Florida | Boca Raton, Florida, United States | Recruiting |
| Brainstorm Research | Miami, Florida, United States | Recruiting |
| Clinical Neuroscience Solutions | Orlando, Florida, United States | Recruiting |
| New England Regional Headache Center | Worcester, Massachusetts, United States | Recruiting |
| Michigan Headache & Neurological Institute | Ann Arbor, Michigan, United States | Not Yet Recruiting |
| FutureSearch Trials of Dallas | Dallas, Texas, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07609914